Serum CEACAM1 Correlates with Disease Progression and Survival in Malignant Melanoma Patients. - Wikidata - wikimedia - TriplyDB

Serum CEACAM1 Correlates with Disease Progression and Survival in Malignant Melanoma Patients.

Serum CEACAM1 Correlates with Disease Progression and Survival in Malignant Melanoma Patients.

http://www.wikidata.org/entity/Q35691891

about

CEACAM1: Expression and Role in Melanocyte Transformation Clinical and experimental studies regarding the expression and diagnostic value of carcinoembryonic antigen-related cell adhesion molecule 1 in non-small-cell lung cancer.Evaluating biomarkers in melanoma.Serum CEACAM1 Level Is Associated with Diagnosis and Prognosis in Patients with Osteosarcoma Serum CEACAM1 Elevation Correlates with Melanoma Progression and Failure to Respond to Adoptive Cell Transfer Immunotherapy.CEACAM1 and MICA as novel serum biomarkers in patients with acute and recurrent pericarditis Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma.Abnormal expression of CD66a promotes proliferation and inhibits apoptosis of human leukemic B cells in vitro.CEACAM1 as a multi-purpose target for cancer immunotherapy.CEACAM1-4L Promotes Anchorage-Independent Growth in Melanoma.Regulation of CEACAM1 Protein Expression by the Transcription Factor ETS-1 in BRAF-Mutant Human Metastatic Melanoma Cells.On the Dual Role of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 (CEACAM1) in Human Malignancies

P2860

Q28072724-10742575-578F-4255-BC3D-54551DF7AA89 Q31123880-71C4834A-204C-4B85-ACAE-07450939994C Q35005677-A933B61F-5FF2-454C-BC4D-023DA5DC33B7 Q35988462-4059FF75-1330-4A23-A58B-26365D41CD1F Q36356547-665E76FD-A7AF-43DE-892C-C483FB2960D8 Q37109625-F4A2FE2A-4EBA-47D2-B806-5F9A44E6F1B1 Q38813507-74AE7341-4A61-41F4-B12A-4614F6EA1717 Q39005994-B4C0B3C1-AAD8-4E1E-83EE-F937185CBECD Q41251368-4471239B-7E01-41C3-B65F-D87E05768018 Q43214725-4653D25C-F7C4-4A9C-BA9B-6EE2F0BA6C2F Q52646586-559241E8-F9FF-4A13-8A2B-13A66407B4D5 Q58567742-C48CB806-636B-45D9-85B5-F5180B8FD5EB

P2860

Serum CEACAM1 Correlates with Disease Progression and Survival in Malignant Melanoma Patients.

http://www.wikidata.org/entity/Q35691891

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Serum CEACAM1 Correlates with ...... n Malignant Melanoma Patients.

@ast

Serum CEACAM1 Correlates with ...... n Malignant Melanoma Patients.

@en

type

label

Serum CEACAM1 Correlates with ...... n Malignant Melanoma Patients.

@ast

Serum CEACAM1 Correlates with ...... n Malignant Melanoma Patients.

@en

prefLabel

Serum CEACAM1 Correlates with ...... n Malignant Melanoma Patients.

@ast

Serum CEACAM1 Correlates with ...... n Malignant Melanoma Patients.

@en

P1433

Q35691891-3530907E-5129-4A48-858A-9DBC9B8E4191

P1476

Q35691891-DD556B8C-4C36-4B32-A75B-E7E65DC4453C

P2093

Q35691891-1EE33411-2BA7-4CCC-B5BB-B42BEF98075C

Q35691891-30BBFEF7-DB51-401A-A25D-5D5933272A18

Q35691891-4F879F11-FA22-43FB-8255-E438AD992A8D

Q35691891-6D63B124-BF40-48A5-B16B-1641BE278FF4

Q35691891-7068FF0D-02BF-46C3-B251-89E6DA217ABB

Q35691891-81041C5B-00D2-4EBD-B0A5-56497297B897

Q35691891-922F81C5-4D53-4268-A9AE-ED2399DE4C0C

Q35691891-AC9E801C-10D0-4444-BCF8-C7D7FB1A3F9A

Q35691891-DBDC2E7C-DFB2-4633-A5B0-ABC676D67F17

P2860

Q35691891-10B82B03-7489-4C32-BBCD-2DDA4E46C3B2

Q35691891-2362CAB9-28F6-43CB-BAA0-AF8D90624E7F

Q35691891-27EFD104-E82C-42BA-B5B6-D0112395FCAF

Q35691891-29D261D6-3CFA-4CA5-867D-61CD25D3AFE5

Q35691891-34690293-C036-453F-90E9-F3AB85CFFA4B

Q35691891-34EE5FBF-BBA9-4A88-A60D-E5239D8A64E4

Q35691891-391C07A1-0989-4A36-8DF7-7A4EDB0A10CD

Q35691891-45863BB4-13A8-4FE5-87F9-6093A76DD740

Q35691891-52521D91-70D8-41BB-BDA8-C226D581CF7F

Q35691891-53FA92A2-F552-4149-87EA-5A5FC37795D8

P304

Q35691891-D091C1CD-F559-4F52-B8A1-A2E2C419BBE0

P31

Q35691891-8551A0DD-E0D4-41F1-9C8F-D64B0540B356

P356

Q35691891-896C8E6B-F9AD-49FB-BF09-5B8C142E0605

P478

Q35691891-CCE52532-CBF7-42DC-937D-02C23D1108AD

P577

Q35691891-79D2874E-8004-45D1-A409-DC6E9D7C2AAF

P5875

Q35691891-2EB21FFF-0102-44C9-BA73-6DCC68EF832E

P698

Q35691891-90000C93-2BF6-4C50-8F6F-99676B4CA782

P932

Q35691891-E89185F6-EEB8-49D7-B752-DC37552636FF

P356

P1433

Clinical and Developmental Immunology

P1476

Serum CEACAM1 Correlates with ...... n Malignant Melanoma Patients.

@en

P2093

Barak Vivian

http://www.w3.org/2001/XMLSchema#string

Faranesh Suzan

http://www.w3.org/2001/XMLSchema#string

Hamburger Tamar

http://www.w3.org/2001/XMLSchema#string

Lotem Michal

http://www.w3.org/2001/XMLSchema#string

Markel Gal

http://www.w3.org/2001/XMLSchema#string

Ortenberg Rona

http://www.w3.org/2001/XMLSchema#string

Peretz Tamar

http://www.w3.org/2001/XMLSchema#string

Sapoznik Sivan

http://www.w3.org/2001/XMLSchema#string

Schachter Jacob

http://www.w3.org/2001/XMLSchema#string

P2860

Biliary glycoprotein, a potential human cell adhesion molecule, is down-regulated in colorectal carcinomas

CEACAM1: contact-dependent control of immunity

The induction of hapten-specific T cell tolerance by using hapten-modified lymphoid cells. I. Characteristics of tolerance induction

Expression of newly identified secretory CEACAM1(a) isoforms in the intestinal epithelium

Tumor vascularity, proliferation, and apoptosis in human melanoma micrometastases and macrometastases.

Cellular source of serum lactate dehydrogenase elevation in patients with thrombotic thrombocytopenic purpura.

S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma.

Progress in the development of immunotherapy for the treatment of patients with cancer.

Close monitoring and lifetime follow-up is optimal for patients with a history of melanoma.

Serum markers to detect metastatic uveal melanoma.

P304

290536

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2012/290536

http://www.w3.org/2001/XMLSchema#string

P478

2012

http://www.w3.org/2001/XMLSchema#string

P577

2012-01-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221793136

http://www.w3.org/2001/XMLSchema#string

P698

22291846

http://www.w3.org/2001/XMLSchema#string

P932

3265158

http://www.w3.org/2001/XMLSchema#string